68 citations,
April 2014 in “Journal of Molecular Endocrinology” The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
50 citations,
December 2006 in “Bone” Exemestane may protect bones by stimulating osteoblast growth through androgen-related pathways.
5 citations,
December 2021 in “Physiological Research” Men, particularly those with hair loss, are more likely to get the virus, and those with prostate cancer may have milder symptoms. Testosterone's role in the disease is unclear, and the virus doesn't seem to harm male fertility. Women with PCOS might be at higher risk. More research is needed.
9 citations,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
60 citations,
May 2011 in “Endocrinology and Metabolism Clinics of North America” Polycystic Ovary Syndrome is linked to higher risk of hypertension and heart disease.
January 2020 in “Elsevier eBooks” Plant-based chemicals may help hair growth and prevent hair loss but need more research to compete with current treatments.
January 2013 in “Dermatologic Clinics” Hair disorders need a holistic approach, including medical, cosmetic, and psychological support.
10 citations,
June 2010 in “Expert Opinion on Drug Metabolism & Toxicology” Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.
3 citations,
April 2017 in “Clinical Drug Investigation” The study found that prescribing patterns for Cyproterone Acetate/Ethinylestradiol in Italy did not significantly change after EMA recommendations.
72 citations,
January 2011 in “Current Pharmaceutical Design” S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.
402 citations,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
15 citations,
May 2020 in “BMC complementary medicine and therapies” Polygonum multiflorum extract helps hair grow longer and fights the effects of hormones that cause hair loss.
21 citations,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
26 citations,
October 2016 in “Clinics in Dermatology” Hormonal treatments can improve acne, but they come with potential side effects and risks.
80 citations,
January 1995 in “The American Journal of Medicine” Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.
82 citations,
May 2016 in “Best Practice & Research in Clinical Obstetrics & Gynaecology” The conclusion is that managing androgen excess requires long-term treatment, including hormonal contraceptives and androgen blockers, with follow-up after six months.
24 citations,
January 2010 in “Annales d'endocrinologie” For women with moderate to severe unwanted hair growth or acne, birth control pills are the first choice, with other medications like cyproterone, spironolactone, flutamide, or finasteride as alternatives, and permanent hair removal should be done with electrolysis or laser.
1 citations,
October 2010 in “Cambridge University Press eBooks” Hormonal therapies are effective for managing hair and skin symptoms in women with PCOS.
5 citations,
May 2017 in “Current Opinion in Pediatrics” Hormonal therapies are safe and effective for treating acne in female adolescents, with specific treatments for those with endocrine disorders.
October 2021 in “The Egyptian Journal of Hospital Medicine ” Combination therapies work better than single treatments for atrophic acne scars.
21 citations,
July 2014 in “Clinics in Dermatology” Hormonal contraceptives can help treat acne by affecting sebum production and androgen levels.
37 citations,
February 2007 in “Clinical Obstetrics and Gynecology” The document concludes that treating PCOS requires a combination of drugs to manage reproductive and metabolic symptoms, with more research needed on combination therapies.
6 citations,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
November 2005 in “Journal of Investigative Dermatology Symposium Proceedings” The 2004 hair research meeting presented new findings on hair cell differentiation, genetic factors in hair loss, hair pigmentation, and potential targeted therapies.
149 citations,
January 2011 in “Nature reviews. Urology” Hormonal interactions, especially involving DHT and estrogen, play a key role in BPH development and treatment.
30 citations,
April 2007 in “Dermatologic Clinics” The document concludes that new treatments are needed to better manage acne and reduce side effects related to current therapies.
306 citations,
August 2011 in “Journal of cachexia, sarcopenia and muscle” Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
31 citations,
September 2006 in “International journal of gynaecology and obstetrics” New treatments for PCOS focus on insulin resistance and reducing testosterone levels, along with traditional hormone therapies.
34 citations,
October 2018 in “Journal of The American Academy of Dermatology” Hormone treatments can help with women's skin and hair disorders, but they need careful monitoring and more research.